Needham & Company LLC Reaffirms “Buy” Rating for Viridian Therapeutics (NASDAQ:VRDN)
Viridian Therapeutics (NASDAQ:VRDN – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at Needham & Company LLC in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $36.00 target price on the stock. Needham & Company LLC’s price target suggests a potential upside of […]
Viridian Therapeutics (NASDAQ:VRDN – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at Needham & Company LLC in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $36.00 target price on the stock. Needham & Company LLC’s price target suggests a potential upside of […]
